EXETER, N.H.--(BUSINESS WIRE)--Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, today announced that Bentley experienced 7% revenue growth when compared to the same quarter of a year ago with record third quarter sales of $25.2 million. The Company incurred charges of $8.9 million in litigation costs, as well as severance and other executive termination charges of $600,000. This contributed to a loss of $7.2 million for the quarter compared to net income of $2.5 million reported in the third quarter of 2005. The loss per share for the 2006 quarter was $0.33, compared to earnings per share of $0.11 for the 2005 quarter.
